Recent News

• 07.20.2026 - Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer
• 07.13.2026 - Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial
• 06.16.2026 - Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044
• 06.02.2026 - Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer
• 06.01.2026 - Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches
• 05.22.2026 - Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors
• 05.04.2026 - Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer
• 04.27.2026 - Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study
• 04.06.2026 - Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer
• 04.01.2026 - Oncolytics Biotech® Completes Domicile Change to the United States

Recent Filings

• 07.20.2026 - 8-K Current report
• 07.20.2026 - EX-99.1 EX-99.1
• 07.13.2026 - 8-K Current report
• 07.13.2026 - EX-99.1 EX-99.1
• 07.08.2026 - 8-K Current report
• 06.16.2026 - 8-K Current report
• 06.16.2026 - EX-99.1 EX-99.1
• 06.03.2026 - 3 Initial statement of beneficial ownership of securities
• 06.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.03.2026 - 4 Statement of changes in beneficial ownership of securities